PDS Biotechnology (NASDAQ:PDSB) Issues Quarterly Earnings Results

PDS Biotechnology (NASDAQ:PDSB) issued its quarterly earnings data on Friday. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02), FiscalAI reports.

PDS Biotechnology Stock Down 12.1%

NASDAQ PDSB traded down $0.12 during trading hours on Friday, reaching $0.86. 4,663,515 shares of the company’s stock traded hands, compared to its average volume of 8,135,308. PDS Biotechnology has a 52-week low of $0.20 and a 52-week high of $1.79. The firm has a market cap of $48.19 million, a PE ratio of -1.35 and a beta of 1.16. The firm has a 50-day simple moving average of $0.97 and a 200 day simple moving average of $0.84. The company has a debt-to-equity ratio of 2.73, a current ratio of 0.57 and a quick ratio of 0.57.

Analysts Set New Price Targets

PDSB has been the topic of several research analyst reports. Wall Street Zen upgraded shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Monday, October 5th. B. Riley Financial reissued a “buy” rating and issued a $4.00 price target (up from $3.00) on shares of PDS Biotechnology in a research note on Thursday, October 29th. Weiss Ratings upgraded shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 28th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of PDS Biotechnology in a research report on Wednesday, August 26th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, PDS Biotechnology presently has an average rating of “Hold” and an average price target of $9.50.

About PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company’s research is based primarily on its Versamune platform, a proprietary technology designed to stimulate targeted immune responses, including the activation of cancer-fighting T cells and natural killer cells. Its lead investigational product, PDS0101, is an immunotherapy candidate designed to target human papillomavirus type 16 (HPV16), a viral strain associated with several cancers.